New FDA rules imperil Bioject | Wall Street Beat April 3, 2012 By drugdelivery Bioject (OTC:BJCT) said it’s unsure of its ability to stay afloat after the FDA instituted new rules last year governing jet injection of vaccines, which accounts for about 70% of Bioject’s business, according to a regulatory filing.
